Rutgers Pharmaceutical Management in the Media
Newark, N.J.
Thursday, September 21, 2017

Walgreens announced Wednesday it will acquire 1,900 Rite Aid locations, including stores in New Jersey and in New York. The acquisition brings a two-year process to a close, as the deal lingered while some worried how boosting Walgreens' store count could affect competitive pricing. But Mahmud Hassan, a professor of finance and economics at Rutgers Business School, said that's less of a concern to him, as he predicts the deal will force Walgreens and CVS to compete for customers and slash prices. 

Read the complete story: 

Globe Newswire
Doylestown, PA
Wednesday, June 14, 2017

Globe NewsWire

Peter Marchesini, Chief Operating Officer of Alamo Pharma Services, will participate in CBI's sixth annual "Bio/Pharma Product Forecasting and Analytics Summit" taking place in Philadelphia on June 15 and 16, 2017. The focus of the summit is to help attendees improve forecasting to optimize revenue potential for pipeline and inline products.

Marchesini, along with Noetyx President and Chief Executive Officer Lenny Vicciardo, will be leading a discussion on "Building an Organizational Infrastructure Based on Long-Term Forecasts."

With more than 20 years' experience in the pharmaceutical industry, Marchesini specializes in helping companies define the smartest plans to effectively address opportunities as they arise to maximize the return on investment. 

Marchesini's expertise is further enhanced by his role on the faculty at Rutgers Business School, where he co-teaches the course Managing the Pharmaceutical Sales Organization, a core course of the Pharmaceutical MBA program.

Full Article

YAHOO! Finance
Bridgewater, NJ
Wednesday, December 21, 2016

YAHOO Finance

Valeritas Holdings, Inc. (VLRX) announced today that Matthew Nguyen, PharmD, has been promoted to chief commercial officer (CCO) to lead the Company's efforts to accelerate adoption of the V-Go® Insulin Delivery device in the United States.

"Matt has been instrumental in driving the success of our recently implemented capital-efficient commercial strategy, which is comprised of a more focused, higher-touch and service sales and marketing effort directed toward high-prescribing physicians.  The commercial team is progressing well with this strategy to expand V-Go utilization within these customers," said John Timberlake, president and chief executive officer of Valeritas.

Dr. Nguyen earned a Bachelor of Science in Pharmacy and a Doctor of Pharmacy from the Philadelphia College of Pharmacy and Science. He also completed a fellowship in health economics and outcomes research in conjunction with Thomas Jefferson University Hospital and Janssen Pharmaceutica, Inc. and earned an MBA from Rutgers Business School.

"During the past year, it has been very gratifying to be part of the successful effort to execute our new commercial strategy and drive V-Go revenue growth in our targeted territories," said Dr. Nguyen. "I now look forward to leading the team to bring V-Go to more patients and their physicians in our currently serviced territories and begin to tactically grow our sales force and add new territories."

Full Article

Newark, NJ
Wednesday, November 9, 2016


In addition to providing MBAs with experience in the pharmaceutical and life sciences industries, an internship at Bayer is designed to allow MBAs to apply their innovation skills to making a difference in patients' lives.

Suraj Adiecha is a Rutgers MBA student who decided to intern at Bayer after visiting the company for a presentation and learning that the company's values aligned with his own. In this interview, Adiecha discusses his experience interning with Bayer, including how building relationships helps get things done within the organization.

Full Article

Newark, NJ
Wednesday, August 10, 2016

Endo Pharma

"We are excited to announce the addition of Joe to the Endo executive team. His industry experience is extensive and includes building commercial businesses, leading multi-function organizations and achieving stellar results across primary care, specialty and rare disease markets. His proven track record of success across nearly 20 product launches and the commercialization of more than 70 products will be instrumental as we continue to focus on strategically growing our U.S. Branded business," said Rajiv De Silva, president and CEO of Endo.

Ciaffoni holds a B.A. in communications and an M.B.A. from Rutgers, The State University of New Jersey.

Full Article

YAHOO Finance
Doylestown, PA
Thursday, July 21, 2016

YAHOO Finance

Peter Marchesini, Chief Operating Officer of Alamo Pharma Services®, participated in CBI's Second Annual Life Sciences Product Launch Summit in Philadelphia. The "Ask the Experts" topic was titled "Learn from Recent Pitfalls to Prepare for Future Product Launches." They thoroughly analyzed recent product launches and discussed the most common and detrimental difficulties anticipated when trying to launch a product and how to possibly avoid them.

This summit was attended by more than 50 leaders in life sciences companies. The goal of CBI's summit was to provide the product launch market with leading-edge, actionable information on the most compelling industry mega and micro trends through exclusive thought leadership presentations from their well-respected speaking faculty and government officials.

"We were honored to be included in this prestigious summit as CBI is known for creating compelling content and personal connections within the Life Science industry," says Marchesini.

Marchesini's expertise is further enhanced by his role on the faculty at Rutgers Business School, co-teaching the course, Managing the Pharmaceutical Sales Organization, which is a core course of the Pharmaceutical MBA program.

Full Article

New Brunswick, NJ
Tuesday, April 5, 2016


A conference next week will shine a light on Halstead Healthcare System, a dominant provider whose footprint is filled with all types of physical assets — from a suburban campus and off-site specialty centers, to recently acquired physician practices and struggling urban hospitals.

The organization also happens to be entirely fictional, part of a theoretical case study hatched by the Rutgers Center for Real Estate that will be the foundation for its second annual conference.

"As part of an academic institution … the Center for Real Estate feels with all of its events that we have to deliver an elevated discussion, a higher level of substance when it hosts a conference or seminar or other event that focuses on real estate," said Ted Zangari, an executive committee member for the center. "So we thought that an issues-packed, fact-driven hypothetical or case study would help us raise the level of discussion to a more substantive level than you might find at some of the other conferences on this topic in the past."

The Future of Healthcare Real Estate Symposium will take place Friday, April 15, at Heldrich Hotel in New Brunswick.

Full Article

Beat the GMAT
Newark, NJ
Tuesday, February 2, 2016

Beat the GMAT
It turns out 2015 was a GREAT year to graduate from business school … and 2016 is looking good too.

The business world increasingly sees MBAs as the key to company success, and this goes beyond the traditional fields like finance and consulting. Innovation is sweeping the healthcare and pharmaceutical industries, and in the process sweeping in MBAs who see working in Big Pharma as a way to change people’s lives for the better. The executive director of careers at Cornell’s Johnson School says recruitment for the industry doubled in 2015, though still small compared to other, more traditional MBA sectors.

Large firms like Johnson & Johnson and Bayer are leading the trend. “We see large firms and start-ups with hiring needs in supply chain, marketing, and finance,” says Dean Vera, director of career management at Rutgers Business School. He says the school’s biggest recruiter is Big Pharma.

Full Article

Washington D.C.
Tuesday, November 24, 2015

In an early-morning call with investors Monday, officers of the two drug-makers portrayed their deal as a boon for health care. Pfizer trumpeted Allergan's strength in drug classes Pfizer had "exited" due to weak returns. The new Pfizer inherits Allergan's pipeline of more than 70 experimental drugs, which includes a new line of biosimilars--essentially me-too versions of existing biotech drugs, says Mahmud Hassan, director of the pharmaceutical management program at Rutgers Business School.

Read the complete story

The Record
Newark, N.J.
Tuesday, November 24, 2015

The two companies say they are looking for $2 billion in savings from the merger. While merged companies tend to focus on cutting duplication, Pfizer and Allergan have distinct drug portfolios - Pfizer with drugs including Viagra and Lipitor and Allergan, which makes Botox - and so not much overlap, said Mahmud Hassan, a finance and economics professor at Rutgers Business School, who specializes in the pharmaceutical industry.

Read the full story

Los Angeles, CA
Friday, August 28, 2015

Los Angeles Times

Are you befuddled by the cost of prescription drugs? There may be a legitimate reason.

"It's certainly not an efficient market," Jason Doctor, an associate professor of pharmaceutical and health economics at USC, said about prescription drug prices. "If it was, you would see only one price for each drug at drugstores, and you don't."

Worse, folks believe that prices for many drugs, both name-brand and generic, keep going up.

According to a recent study by Consumer Reports, one-third of patients said the cost of their usual prescription rose $39 on average over the last year. One in 10 said they're now paying at least $100 more than they did a year ago.

Among the drugs that saw the biggest jumps in prices were treatments for common ailments such as asthma, high blood pressure and diabetes.

I asked about a dozen experts whether the drug market was rigged against consumers. The answer, surprisingly, was no. But they said there were steps that could be taken to improve things.

"I think everyone would agree that the price of many branded drugs is way too high," said Mahmud Hassan, a healthcare economist at Rutgers Business School. "But we still have the cheapest generic drugs in the world."

Full Article

Poets & Quants
New York, NY
Saturday, March 14, 2015

Poets & Quants

There’s far more to an MBA case competition than the battle among students and schools. While there is plenty to be learned from working under the gun on a dreadfully tight deadline, there’s at least as much to be gained, career-wise, from participating an event that typically brings together dozens or hundreds of very bright, connected people, and highly engaged company representatives on the lookout for new talent.

Most case competitions follow a theme, which can vary from supply chain, to finance, to sustainability, to health care, to real estate. Some take place over a weekend; others are conducted in stages, over weeks. Some competitions are invitation-only, others are by application.
Aspen Institute Case Competition trophies

But while the focuses and formats of case competitions can vary quite widely, they all share a dual purpose: to advance students’ business skills, and to help students build connections that will aid in their career development. Many opportunities exist at each competition – often including organized networking events – to interact with peers from other schools, and representatives from sponsoring companies who often use their participation for recruiting.

Full Article

Pharmacy Choice
Newark, NJ
Monday, December 8, 2014

Rutgers MBA students Mittal Shah and Sonal Patel were sitting next to one another in Rutgers Business School's Bove Auditorium as the winners of the annual biopharmaceutical case competition were announced on the afternoon of Nov. 14.

Within a few minutes, they knew that Kellogg had won third place. And then, Wharton was announced as the second-place winner.

The women looked at one another, nervously wondering where the team from Rutgers Business School would place. "It's going to be all or nothing," Patel said softly, waiting for the next winner to be announced.

When Rutgers was declared the first place winner, Shah and Patel leaped out of their chairs and hugged one another. The room erupted with applause for the home team, which also included Michael Kwatkoski, Paul Rosiak and Kinushuk Saxena, the team's sole first-year MBA student. All five students are pursuing MBAs in Rutgers Business School's top-ranked Pharmaceutical Management program.

The third annual biopharmaceutical case competition at Rutgers attracted teams from the nation's leading business schools, including Wharton, Columbia and Kellogg. Teams also represented Michigan State University, MIT Sloan, Duke, Penn State's Smeal College of Business and the University of Georgia's Terry College of Business.

After just a few years, Rutgers Business School's case competition has become known as an important one for MBA students hoping to move into careers in the healthcare and pharmaceutical fields. The competition has multiple company sponsors, intensifying the networking aspect of the day and the potential for students to impress major companies.

Full Article
Newark, NJ
Tuesday, July 29, 2014

Since Merck’s companywide restructuring last fall that included laying off thousands of workers, closing locations and sharpening its focus on research and development, Chief Executive Kenneth Frazier has maintained the sweeping changes would require time to pay off.

“In the longer term, we see some good things coming up from the research wing through alliances, through small acquisitions,” said Rutgers Business School professor Mahmud Hassan, who follows the pharmaceutical industry. “These will help put off all of Merck’s uncertainties, I hope.”

Merck’s recent strategy shift and drug rollout plans, Hassan said, have renewed his optimism in the company.

“They reorganized, took some bold steps and I think those are now starting to pay off.”

Full Article
Newark, NJ
Wednesday, October 2, 2013

In a statement about its global cost-cutting plan, Merck, the second-largest U.S. drugmaker said the cuts were part of an effort to sharpen “commercial and R&D (research and development) focus and reduce costs,” including the size of its workforce and global real estate footprint.

In a conference call, Merck Chief Executive Ken Frazier said the company will place more emphasis on developing drugs with the most sales potential, which means getting the business side to work more closely with researchers, he said. But Rutgers Business School professor Mahmud Hassan wondered what took so long. “Merck’s been limping along for the last several years, relying on one drug, Januvia,” he said. Sales of that blockbuster diabetes medication are now being threatened as several new competitors are in the final stages of development or scheduled to debut their own versions in the next two years.

Hassan added that Merck’s decision to lay off thousands of workers was a short-term fix, and that trying to sell off properties will be a difficult proposition in the current economy.

Full article

Berlin, Germany
Tuesday, August 20, 2013

“For the people who have done well, they've had science backgrounds or experience in the healthcare industry,” says Mahmud Hassan, Director of the Rutgers MBA in Pharmaceutical Management, adding that “they may have worked not directly with the pharma industry, but indirectly, like as a consultant, or as a researcher.”

Graduates of the Rutgers program by and large go into “Big Pharma” firms – giants like Pfizer, Novartis, and GlaxoSmithKline, which, from a revenue standpoint, make up a large percentage of the industry. These companies are so large and sprawling that they can offer jobs for MBA graduates with an array of interests, from roles in research and development and drug delivery management to corporate finance and marketing.

Because the pharmaceutical industry is so large and complex, a huge variety of jobs await well-prepared MBA graduates. In the Rutgers MBA program, students who specialize in pharmaceuticals can also choose a second concentration, usually focusing on a functional area.

“Supply chain and marketing – those are the most popular combinations,” says Hassan, who notes that a good number of other pharma students
pursue a finance concentration.

Read full article.

Monday, April 1, 2013

Although Dental Health Associates CEO and President Dr. Clifford Lisman jokingly describes his approach to business as "winging it," he is taking steps to enhance his knowledge while working to improve the acumen of his staff. In 2012, Lisman began an executive MBA program at Rutgers University. "I've spent considerable time studying business on an informal basis for years, but I'm now looking to supplement my life experience with more formal experience in terms of business management," he says.

Continue reading

Friday, November 9, 2012

Teams from 11 business schools, including Georgetown and Columbia, have signed up to compete in the school's first biopharmaceutical case competition.

The day-long competition will be held Nov. 10 at Rutgers Business School's $83 million facility in Newark, NJ.

The teams will be competing for cash prizes as well as the recognition of some of the industry's leading companies.

"It brings another layer of national exposure to the school,'' says Chris Parker, a Rutgers MBA student who competed at Kellogg School of Management earlier this year.  As co-president of the pharmaceutical club, Parker helped to organize the competition being hosted by Rutgers.

Parker says Rutgers will follow what has become "the gold standard'' for pharmaceutical case competitions: Each team will have a week to prepare after receiving a case study that reflects a current, real-life marketing or operational issue faced by the industry.

Tuesday, December 27, 2011

"We expected growth to continue, but it didn't," said Mahmud Hassan, professor of finance and economics at Rutgers Business School, who has been tracking the health care industry for decades. "It hasn't grown as much as people thought it would."

Monday, August 8, 2011

Local nonprofit hospitals are making the controversial move to join forces with for-profit institutions, such as those in Massachusetts under the recent Steward Health Care System buying spree.

"When a hospital becomes a for-profit, what is the pay-off?" said Rutgers School of Business professor Mahmud Hassan in the article. "There will be an inflow of cash by the investors and improvements made at the hospital...But what does this mean for the community and the society once the hospital's status changes? The for-profit hospital is going to eliminate some services that are unprofitable. They will restrict indigent care." He continued, "Only time will tell if this is ultimately good or bad for the society."

Read the full article